CARGISEMA is an investigational, novel, long-acting acylated amylin analog that acts as a non-selective agonist of amylin receptors (AMYR) and calcitonin G-protein-coupled receptors (CTR). Cagrilintide induces significant weight loss and reduces food intake.

According to a phase II study of the drug CagriSema (NCT04982575), the combination therapy resulted in weight loss in 32. week of treatment by 15.6% from baseline. . These results suggest that CagriSema is likely to cause a greater change in body weight from baseline than even the highest dose of Tirzepatide, over a fixed period of time.
The initiation of this Phase III comparative trial may suggest that CagriSema and Tirzepatide will become direct competitors and will be specifically approved for patients with a body mass index (BMI) of 30 or higher (obese) or overweight patients with one or more weight-related comorbidities, such as type 2 diabetes, high cholesterol, high blood pressure, respiratory problems or cardiovascular disease. Since CagriSema is still in clinical development, its future patient population has yet to be determined. However, in clinical trials, combination therapy is being studied in both obese and overweight patients.

The substance is not a food product or dietary supplement, it is not suitable for human consumption. The product is classified as a chemical reagent approved for marketing in the European Union, and can only be used for scientific research.



There are no reviews yet.

Be the first to review “CARGISEMA 5+5mg”

Your email address will not be published. Required fields are marked *